Abstract
Abstract. Background: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy. Methods. A total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4 Korean institutions were included. Results: Thirty-six patients (30.5%) had a low absolute lymphocyte count (ALC, < 1.0 × 10 9 /L) at diagnosis. Patients with lymphopenia had shorter overall survival (OS) and progression-free survival (PFS) rates compared with patients with high ALCs (P = 0.003, P = 0.012, respectively). In multivariate analysis, high-intermediate/ high-risk International Prognostic Index (IPI) scores and lymphopenia were both associated with shorter OS and PFS. Treatment-related mortality was 25.0% in the low ALC group and 4.8% in the high ALC group (P = 0.003). In patients considered high-intermediate/high-risk based on IPI scores, lymphopenia was also associated with shorter OS and PFS (P = 0.002, P = 0.001, respectively). Conclusion: This study suggests that lymphopenia could be an independent prognostic marker to predict unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can be used to further stratify high-risk patients using IPI scores.
| Original language | English |
|---|---|
| Article number | 34 |
| Journal | Journal of Hematology and Oncology |
| Volume | 4 |
| DOIs | |
| Publication status | Published - 2011 Aug 17 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hematology
- Molecular Biology
- Oncology
- Cancer Research
Cite this
}
Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy. / Kim, Yu Ri; Kim, Jinseok; Kim, Soo Jeong; Jung, Hyun Ae; Kim, Seok Jin; Kim, Won Seog; Lee, Hye Won; Eom, Hyeon Seok; Jeong, Seong Hyun; Park, Joon Seong; Cheong, June Won; Min, Yoo Hong.
In: Journal of Hematology and Oncology, Vol. 4, 34, 17.08.2011.Research output: Contribution to journal › Article
TY - JOUR
T1 - Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy
AU - Kim, Yu Ri
AU - Kim, Jinseok
AU - Kim, Soo Jeong
AU - Jung, Hyun Ae
AU - Kim, Seok Jin
AU - Kim, Won Seog
AU - Lee, Hye Won
AU - Eom, Hyeon Seok
AU - Jeong, Seong Hyun
AU - Park, Joon Seong
AU - Cheong, June Won
AU - Min, Yoo Hong
PY - 2011/8/17
Y1 - 2011/8/17
N2 - Abstract. Background: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy. Methods. A total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4 Korean institutions were included. Results: Thirty-six patients (30.5%) had a low absolute lymphocyte count (ALC, < 1.0 × 10 9 /L) at diagnosis. Patients with lymphopenia had shorter overall survival (OS) and progression-free survival (PFS) rates compared with patients with high ALCs (P = 0.003, P = 0.012, respectively). In multivariate analysis, high-intermediate/ high-risk International Prognostic Index (IPI) scores and lymphopenia were both associated with shorter OS and PFS. Treatment-related mortality was 25.0% in the low ALC group and 4.8% in the high ALC group (P = 0.003). In patients considered high-intermediate/high-risk based on IPI scores, lymphopenia was also associated with shorter OS and PFS (P = 0.002, P = 0.001, respectively). Conclusion: This study suggests that lymphopenia could be an independent prognostic marker to predict unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can be used to further stratify high-risk patients using IPI scores.
AB - Abstract. Background: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy. Methods. A total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4 Korean institutions were included. Results: Thirty-six patients (30.5%) had a low absolute lymphocyte count (ALC, < 1.0 × 10 9 /L) at diagnosis. Patients with lymphopenia had shorter overall survival (OS) and progression-free survival (PFS) rates compared with patients with high ALCs (P = 0.003, P = 0.012, respectively). In multivariate analysis, high-intermediate/ high-risk International Prognostic Index (IPI) scores and lymphopenia were both associated with shorter OS and PFS. Treatment-related mortality was 25.0% in the low ALC group and 4.8% in the high ALC group (P = 0.003). In patients considered high-intermediate/high-risk based on IPI scores, lymphopenia was also associated with shorter OS and PFS (P = 0.002, P = 0.001, respectively). Conclusion: This study suggests that lymphopenia could be an independent prognostic marker to predict unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can be used to further stratify high-risk patients using IPI scores.
UR - http://www.scopus.com/inward/record.url?scp=80051580303&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051580303&partnerID=8YFLogxK
U2 - 10.1186/1756-8722-4-34
DO - 10.1186/1756-8722-4-34
M3 - Article
VL - 4
JO - Journal of Hematology and Oncology
JF - Journal of Hematology and Oncology
SN - 1756-8722
M1 - 34
ER -